Background. Human monocytic ehrlichiosis (HME) is a potentially life-threatening tick-borne illness. HME-associated hemophagocytic lymphohistiocytosis (HLH) is a rare entity with a paucity of published literature regarding treatment and outcome. We present the clinical features, treatment, and outcomes of 4 patients at our institutions with HME-associated HLH. This review also summarizes the current literature regarding the presentation, treatment, and outcome of this infection-related HLH. Methods. We searched the PubMed database for case reports and case series. All cases were diagnosed according to the HLH-04 criteria. Results. Four cases of HME-associated HLH were included from our institutions. The literature review yielded 30 additional cases. About 41% of the cases were in the pediatric population; 59% were female; and all patients had fever, cytopenia, and elevated ferritin. Most patients were immunocompetent; all but one patient with available data were treated with doxycycline, and eight of the patients with available data received the HLH-94 treatment protocol. The mortality rate was 17.6%. Conclusions. HME-associated HLH is a rare but serious syndrome with significant mortality. Early treatment with doxycycline is critical, but the role of immunosuppressive therapy is individualized.

Background Kansas ranks as the 8th-worst state nationally for outpatient antibiotic prescribing, with a rate of 690 antibiotic prescriptions per 1000 population. The statewide rate of fluoroquinolone (FQ) is disproportionately higher than other antibiotic drug classes. Statewide antibiograms can be developed by health departments for antimicrobial stewardship monitoring. The purpose of this study was to investigate the correlation between the FQ resistance rate of gram-negative bacteria to FQ consumption. Methods A retrospective design utilizing 2018-2019 county level FQ-resistant Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa was categorized by county level based on the Kansas statewide antibiogram. Outpatient FQ utilization data was obtained from IQVIA and categorized into county level FQ rate based on prescriptions dispensed per 1000 population. Linear regression was used to compare antibiotic resistance (AR) to FQ utilization by county. Results Sixty-six of 123 facilities contacted for antibiogram data responded with results. Of these, 47 were critical access hospitals, and the rest were acute care hospitals or clinics. A total of 31,573 E. coli isolates, 5,942 K. pneumoniae and 5,017 P. aeruginosa isolates were represented. All 106 counties had FQ prescription data. Of the 49 counties with AR reported, FQ rates ranged from 4.6 to 105.6/1000 population. There was no statistical significance associated between counties for FQ-resistant E. coli, K. pneumoniae or P. aeruginosa with FQ-utilization rates (p=0.184, 0.572, 0.352, respectively). Comparing urban and rural regions was also compared for each AR-FQ use combination. There was statistical significance for urban P. aeruginosa FQ-resistance and FQ utilization (p=0.025), but not for urban E. coli (p=0.120) or urban K. pneumoniae (p=0.331). Conclusion A strong correlation was demonstrated between FQ consumption and rates of FQ-resistant P. aeruginosa within urban counties. No significant correlations were found between FQ consumption rates and other organisms. This study demonstrates additional applications for state-level antibiogram data, particularly when paired with antibiotic use data. Disclosures All Authors: No reported disclosures.